Compared with the full-effector Aβ-targeting antibodies, AβO-specific single-chain variable fragment (scFv) antibody may show promise in treating AD due to lack of Fc fragment, which would avoid inflammatory response and other potential side effects. This evidence concerns the gene ABO and Alzheimer disease.